CareRx Reports Results for the Third Quarter of 2025

Executive Summary

• CareRx reported Q3 2025 revenue of C$93.2 M, up from C$91.4 M in Q2 2025 and C$92.8 M YoY.
• Adjusted EBITDA rose to C$8.3 M (9.0% margin), improving both quarter‑over‑quarter and year‑over‑year.
• The company declared a quarterly dividend of $0.02 per share, renewed its NCIB for up to 1.5 million shares, and repurchased 194,100 shares at a weighted‑average price of $3.56.

Key Details

• Average Beds Serviced: 91,298 as of Sept 30 2025 (up 1,250 Q2 2025; up 2,199 YoY).
• Revenue: C$93,220 k (Q3 2025) vs. C$92,836 k (Q3 2024).
• Adjusted EBITDA: C$8,345 k (9.0% margin) vs. C$7,775 k (8.4%) in Q3 2024.
• Adjusted EBITDA per share – Basic: $0.13 (unchanged YoY).
• Net Income: C$1,550 k (vs. a loss of C$(360) k in Q3 2024).
• Cash from Operations: C$10,076 k (down from C$12,240 k Q3 2024).
• Total Assets / Liabilities: $223,672 k assets; $136,406 k liabilities.
• Net Debt: C$28,768 k (down from C$44,262 k Q3 2024); Net Debt/Adj‑EBITDA = 0.86x (improved from 1.42x).
• Dividend: $0.02 per common share declared Sept 15 2025; paid Oct 15 2025 (eligible dividend).
• NCIB Renewal: TSX approved renewal; company may repurchase up to 1,500,000 shares Sep 17 2025 – Sep 16 2026. Repurchased 194,100 shares at $3.56 avg price.
• Conference Call: Scheduled for Tue Nov 4 2025, 8:30 a.m. ET; webcast available on Investors page (archived 90 days).

Notable Quotes

“Our third quarter results demonstrate the continued momentum we have built through disciplined execution and strategic investments in our operating platform,” said Puneet Khanna, President & CEO.
“The initiation of a quarterly dividend and the renewal of our share buyback program underscore our confidence in the business…”

All non‑material boilerplate, forward‑looking statements, and company background have been omitted.